ClinicalTrials.gg
Not yet recruitingNCT06769984Updated Jan 10, 2025

A Study of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease.

A Phase 1/2 interventional study of SCTT11 and Placebo in TED, sponsored by Sinocelltech Ltd.. Not yet recruiting. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-10.

Sponsored by Sinocelltech Ltd. (part of Sinocelltech Group Limited) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Multicentre, Randomized, Double-blinded, Phase I/II Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease

02

Conditions studied

  • TED
03

In context

Lead sponsor

Sinocelltech Ltd. is the lead sponsor of 82 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria for Healthy Participants:

  1. Healthy male or female participants aged between18 and 45 inclusive
  2. All participants must agree to not fall pregnant and voluntarily use highly effective double method during the study for at least 180 days after the last dose; female participants must have a negative pregnancy test prior to dosing and must not be breastfeeding

Exclusion Criteriafor Healthy Participants:

1.With any other disease or medical condition of clinical significance (e.g., past medical history of chronic hepatic, renal, cardiovascular, neurological/psychiatric, gastrointestinal, respiratory, urological, endocrinological, or other systemic diseases, etc.) as assessed by the investigator.

Inclusion Criteria for TED Participants:

  1. Male or female participants aged between 18 and 70 inclusive
  2. Participants with moderate-to-severe (has an appreciable impact on daily life and requires intervention, but is not sight-threatening) TED
  3. Normal thyroid function, or only mild hyperthyroidism or hypothyroidism (defined as screening free triiodothyronine [FT3] and free thyroxine [FT4] levels \< 50% above or below the normal limits).

Exclusion Criteria for TED Participants:

  1. Decreased best corrected visual acuity of the study eye due to optic neuropathy within 6 months prior to the first dose
  2. Corneal abnormalities in study eye with no relief from treatment, as evaluated by the investigator
  3. A reduction of ≥2 points in the CAS value or a reduction of ≥2 mm in proptosis in the study eye from the screening assessment period to study baseline period
  4. Presence of other ocular conditions that, in the judgement of the investigator, may affect the evaluation of the study results
  5. Presence of poorly controlled diabetes mellitus
  6. The current presence of other uncontrolled clinical diseases or conditions
  7. Abnormalities in any of the following laboratory examinations during the screening phase
  8. Poorly controlled hypertension
  9. With past medical histories of major surgery and/or trauma within 1 month prior to the first dose
  10. With past medical histories of severe allergies, histories of severe drug allergies, known or suspected allergy to any component of this product
  11. Vaccination with live or within 1 month prior to the first dose or expected during the study
  12. Participation in a clinical study of any drug or device within 3 months prior to the first dose and have used the investigational product or have been treated with the device
  13. Pregnant, lactating females; or participants of who are unwilling to use effective contraception during the study and within 180 days after the last dose
  14. Other conditions evaluated by the investigator to be unsuitable for enrolment
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    SCTT11 dose 1, dose 2, dose 3, dose 4

    Drug: SCTT11

  • Placebo comparator
    Placebo dose 1, dose 2, dose 3, dose 4

    Drug: Placebo

Interventions

  • DrugSCTT11

    SCTT11 dose 1, dose 2, dose 3, dose 4

  • DrugPlacebo

    Placebo dose 1, dose 2, dose 3, dose 4

06

What researchers measure

Primary outcomes

  1. The occurrences of treatment-emergent adverse events (TEAE), treatment-related TEAE (TRAE), serious adverse events (SAE), and adverse events of special interest (AESI)

    Time frame: Day 0 up to 85 days for healthy participants

  2. Proptosis Responder Rate in the study eye

    Proptosis Responder Rate in the study eye (i.e., reduction of proptosis of ≥ 2 mm from baseline without a corresponding increase of ≥ 2 mm in the fellow eye\] as measured by exophthalmometer)

    Time frame: Day 0 up to 169 days

Secondary outcomes

  1. Change from baseline in proptosis in the study eye as measured by exophthalmometer

    Time frame: Day 0 up to 169days

  2. Change from baseline in Clinical Activity Score (CAS)

    Time frame: Day 0 up to 169days

  3. Diplopia Responder Rate

    Diplopia Responder Rate (i.e., reduction in Gorman Subjective Diplopia Score of ≥1 from baseline for participants with baseline Gorman Subjective Diplopia Score \>0)

    Time frame: Day 0 up to 169days

  4. Proportion of participants with a CAS of zero or one in the study eye

    Time frame: Day 0 up to 169days

  5. SCTT11 concentrations in the blood over time

    Time frame: Day 0 up to 169days

  6. Incidence of anti-drug antibody (ADA) development in SCTT11-treated participants over time

    Time frame: Day 0 up to 169days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2025; primary completion for Jun 2026, 16 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2025
First posted
Jan 10, 2025
StartEst.
Feb 19, 2025
Primary completionEst.
Jun 24, 2026
CompletionEst.
Sep 19, 2028
Last update
Jan 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06769984
Lead sponsor
Sinocelltech Ltd.
Responsible party
Sponsor
First posted
Jan 10, 2025
Start date
Feb 19, 2025 (estimated)
Primary completion
Jun 24, 2026 (estimated)
Completion
Sep 19, 2028 (estimated)
Last update
Jan 10, 2025

Study contacts

Ming Guo
Contact
ming_guo@sinocelltech.com
+86-10-58628288-9127

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion